Inrebic

Fedratinib, the active ingredient in Inrebic, is a JAK2 inhibitor presented as a tablet for oral use. It treats primary or secondary myelofibrosis in adult patients.\n\nGNH India supplies Inrebic as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Inrebic acts on the JAK‑STAT pathway to manage myelofibrosis, a chronic myeloproliferative disorder.\n\nPrimary myelofibrosis: reduces spleen size and alleviates disease‑related symptoms.\nSecondary myelofibrosis: provides disease control in patients who have progressed from other myeloproliferative neoplasms.\nMyeloproliferative neoplasm progression: helps delay progression of disease in eligible patients.

Common Side Effects:\n- Fatigue\n- Diarrhea\n- Nausea\n- Anemia\n- Thrombocytopenia\n- Headache\n\nSerious or Rare Side Effects:\n- Wernicke encephalopathy\n- Severe infections\n- Hepatic toxicity\n- Tumor lysis syndrome\n- Cardiac failure\n- Pulmonary hypertension

Before initiating therapy, clinicians should assess baseline blood counts and liver function.\n\nMonitor blood counts: perform regular CBC to detect anemia or thrombocytopenia.\nAssess for Wernicke encephalopathy: watch for confusion, ataxia, or ophthalmoplegia.\nEvaluate liver function: check hepatic enzymes periodically.\nReview concomitant CYP3A4 inhibitors: adjust dose or avoid if strong inhibitors are used.\nStore at ambient temperature: keep in the original pack, protect from moisture.

Fedratinib may interact with several drug classes that affect its metabolism or safety profile.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Fedratinib exposure.\n- Anticoagulants (e.g., warfarin): heightened bleeding risk.\n- Other JAK inhibitors: additive immunosuppression.\n\nModerate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment.\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.